AVBP
ArriVent BioPharma, Inc.Company Information
- Company Name
- ArriVent BioPharma, Inc.
- CIK
- CIK0001868279
- Category
- Non-accelerated filer<br>Emerging growth company
- Ticker: Exchange
- AVBP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AVBP
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-01-30
- Last sale
- 2025-12-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 555,555
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,200,892
- Shares outstanding
- 47,606,857
- Ownership
- 97.05%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -1.62%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 155 | 62 | 46 | 113 | 113 | 50 | 74 | 283 | 299 | 317 | ||||||
| Short Term Investments | 218 | 264 | 267 | 188 | 123 | 126 | 145 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 21 | 22 | 20 | 21 | 14 | 10 | 8 | 10 | 10 | 10 | ||||||
| Assets Current | 394 | 349 | 333 | 321 | 250 | 186 | 227 | 292 | 309 | 327 | ||||||
| Long Term Investments | - | - | - | 5 | 19 | 29 | 48 | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 395 | 349 | 333 | 327 | 270 | 215 | 275 | 293 | 309 | 328 | ||||||
Liabilities Current | ||||||||||||||||
| Accounts Payable Current | 2 | 9 | 6 | 6 | 4 | 4 | 4 | 5 | 4 | 4 | ||||||
| Accrued Liabilities Current | 25 | 16 | 20 | 16 | 15 | 8 | 13 | 10 | 8 | 6 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 28 | 25 | 26 | 22 | 20 | 13 | 17 | 15 | 12 | 10 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 28 | 25 | 26 | 22 | 20 | 13 | 17 | 15 | 12 | 10 | ||||||
Stockholders Equity | ||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 865 | 772 | 712 | 674 | 584 | 505 | 496 | 495 | 494 | 493 | ||||||
| Retained Earnings Accumulated Deficit | -498 | -448 | -405 | -369 | -334 | -303 | -238 | -218 | -197 | -175 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | -0 | - | - | - | ||||||
| Stockholders Equity | 367 | 324 | 307 | 305 | 250 | 203 | 258 | 277 | 297 | 318 | ||||||
| Liabilities And Stockholders Equity | 395 | 349 | 333 | 327 | 270 | 215 | 275 | 293 | 309 | 328 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Seriesa Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 48 | 45 | 42 | 41 | 37 | 34 | 34 | 34 | 34 | 33 | ||||||
| Shares Outstanding | 48 | 45 | 42 | 41 | 37 | 34 | 34 | 34 | 34 | 33 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialArriVent BioPharma, Inc. (AVBP) — SEC Financial Statements & Analysis
ArriVent BioPharma, Inc. (AVBP) is a pharmaceutical preparations company, incorporated in DE. ArriVent BioPharma, Inc. trades on Nasdaq as: AVBP. ArriVent BioPharma, Inc. (AVBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, ArriVent BioPharma, Inc. carries a market cap of $1.65B, a P/E ratio of -10.10x, a P/B ratio of 4.51x, an enterprise value of $1.50B, and an EV/EBITDA multiple of -8.47x. On profitability, it posts a Return on Equity (ROE) of -53.10%, a Return on Assets (ROA) of -49.30%, and a Return on Invested Capital (ROIC) of -100.75%. Per share, it reports EPS of $-3.44, diluted EPS of $-3.44, free cash flow per share of $-3.11, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 19.53% year-over-year and EPS growth of -12.11% year-over-year. On the balance sheet, it maintains a current ratio of 14.16x, a quick ratio of 13.40x, working capital of $366.33M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, free cash flow of $-147.93M (TTM), and net debt of $-154.68M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.65B
- P/E TTM
- -10.10x
- EPS TTM
- $-3.44
- P/B TTM
- 4.51x
- ROE TTM
- -53.10%
- ROA TTM
- -49.30%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-147.93M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ArriVent BioPharma, Inc. in?
ArriVent BioPharma, Inc. (AVBP) operates in the Pharmaceutical Preparations industry.
What exchange does AVBP trade on?
ArriVent BioPharma, Inc. (AVBP) trades on the Nasdaq.
Where is ArriVent BioPharma, Inc. incorporated?
ArriVent BioPharma, Inc. is incorporated in DE.
When was ArriVent BioPharma, Inc. (AVBP)'s most recent SEC filing?
ArriVent BioPharma, Inc. (AVBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is AVBP's market cap?
ArriVent BioPharma, Inc. (AVBP) has a market capitalization of $1.65B as of 2026-06-30.
What is AVBP's EPS (earnings per share)?
ArriVent BioPharma, Inc. (AVBP)'s trailing twelve month EPS is $-3.44 as of 2026-06-30.
What is AVBP's ROE (return on equity)?
ArriVent BioPharma, Inc. (AVBP)'s trailing twelve month Return on Equity (ROE) is -53.10% as of 2026-06-30.
What is AVBP's ROA (return on assets)?
ArriVent BioPharma, Inc. (AVBP)'s trailing twelve month Return on Assets (ROA) is -49.30% as of 2026-06-30.
What is AVBP's ROIC (return on invested capital)?
ArriVent BioPharma, Inc. (AVBP)'s trailing twelve month Return on Invested Capital (ROIC) is -100.75% as of 2026-06-30.
What is AVBP's EV/EBITDA?
ArriVent BioPharma, Inc. (AVBP)'s trailing twelve month EV/EBITDA is -8.47x as of 2026-06-30.